GlassScriptPhysician profile
David L Tate
NPI 1093708802
$10,896.03
in general payments reported to CMS, 2019-2025
58 companies · $2,015 in 2025
The $2,015 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $841 · 2021: $1,470 · 2022: $1,431 · 2023: $1,454 · 2024: $1,826 · 2025: $2,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,295.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,603.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $923.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $764.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $644.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $637.16 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $622.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $601.65 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $539.75 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $512.15 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $502.70 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $347.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $271.59 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $186.93 | 2023-2025 | Rexulti |
| Noven Therapeutics, LLC | $180.74 | 2023-2025 | Xelstrym |
| Esperion Therapeutics, INC. | $167.70 | 2020-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.